Its a big pharma showdown as health care analyst David Williamson discusses whether Merck (NYSE: MRK) or Pfizer (NYSE: PFE) is the better buy. Both stocks have a lot going for them, Merck an exciting pipeline featuring a likely first to market immuno-oncology drug, a hepatitus-c cure, and even a potential treatment for Alzheimer's. Pfizer has a sizable cash horde and an aggressive management team. While losing out on the lower taxes an AstraZeneca deal would have brought, shareholders can look forward to buybacks dividends and a possible huge expansion of its pneumonia vaccine.

Watch and find out in this episode of Market Check-Up, the Motley Fool's health care focused investing show which of these two stocks is the winner.